Does TRT affect the prostate?
Modern longitudinal evidence does not support the older claim that TRT causes prostate cancer. Provider-reviewed TRT requires baseline PSA, prostate-history review, and PSA monitoring on the recalibration cadence. Active prostate cancer is a contraindication; benign prostatic patterns are individually reviewed.
Full answer
The historical assumption that testosterone fuels prostate cancer has not been supported by modern longitudinal evidence. Current clinical consensus is that provider-reviewed TRT in candidates without active prostate cancer does not increase prostate cancer risk in aggregate. Provider-reviewed optimization requires baseline PSA, a prostate and urologic history review, and PSA monitoring on the recalibration cadence. Active prostate cancer is a contraindication. A meaningful PSA velocity change during optimization triggers urology referral. Benign patterns — mild BPH, prior elevated PSA without malignancy — are individually reviewed and do not automatically disqualify candidacy.
Educational. Not a substitute for individualized provider review.
- Testosterone optimization pathway — Primary source · oMeds
- Reviewed by Dr. Laura Purdy, MD, MBA · Clinical Director, oMeds · Last reviewed 2026-05-29